Swedish group that distributes and develops medical technology and diagnostics products, mainly through acquired niche companies.
Swedish group that distributes and develops medical technology and diagnostics products, mainly through acquired niche companies.
Grows mainly by buying small niche distributors and leaving them to run themselves, each earning a distribution margin on suppliers' products plus service, so group results track many local customer relationships rather than a few products.
In one line: A Nordic medtech distribution roll-up like a smaller Henry Schein.
Moat: narrow (distribution, customer qualification). Decentralized portfolio of niche distribution businesses with local customer relationships, but distribution has thin structural moats.
Headquarters: Stockholm, Sweden · Founded: 1990 · Employees: 2,295
Size AddLife (ALIF-B.ST) is a Sweden Health Care company (Medical/Nursing Services) with a market value of $2.13B, the 79th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 177.40 on 18 Nov 2026.
Performance Over six months the shares gained 15.4%, against +22.3% for the median peer and +2.8% for the Sweden market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 1.6% over the last twelve months (peer median +9.2%); the operating margin is 7.7% (peer median 5.3%).
Valuation It trades at 39.0× forward earnings against a peer median of 33.8× (8th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points below its cost of capital (9.5% WACC).
Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 10.7B | SEK 10.4B | SEK 10.3B | SEK 9.69B | SEK 9.08B |
| Revenue growth | — | +2% | +6% | +7% | — |
| Gross profit | SEK 4.14B | SEK 3.27B | SEK 3.14B | SEK 2.77B | SEK 2.78B |
| EBITDA | SEK 1.63B | SEK 1.61B | SEK 1.53B | SEK 1.46B | SEK 1.45B |
| Net income | SEK 644M | SEK 560M | SEK 252M | SEK 190M | SEK 480M |
| Free cash flow | SEK 1.13B | SEK 1.15B | SEK 845M | SEK 547M | SEK 696M |
| Capital expenditure | SEK 309M | SEK 284M | SEK 297M | SEK 308M | SEK 282M |
| Total debt | SEK 5.14B | SEK 4.77B | SEK 5.07B | SEK 5.29B | SEK 5.59B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| AddLife ALIF-B.ST | $2.13B | +15% | +2% | 8% | 39.0× | 21.1% |
| Henry Schein HSIC | $9.47B | +17% | +6% | 6% | 14.7× | 10.2% |
| Asker Healthcare ASKER.ST | $2.69B | -14% | +12% | 7% | 24.8× | 4.7% |
| Avantor AVTR | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALIF-B.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | -0.3% | 10th lowest of 21 |
| 6-month return | +15.4% | +22.3% | 8th lowest of 21 |
| Distance from 52-week high | -8.0% | -22.4% | 7th highest of 21 |
| Revenue growth (TTM) | +1.6% | +9.2% | 6th lowest of 21 |
| Operating margin | 7.7% | 5.3% | 10th highest of 21 |
| Forward P/E | 39.0× | 33.8× | 8th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 21.1% | 5.4% | 5th most demanding of 16 |
| Growth delivered (Del g) | +14.6% | +7.7% | 4th highest of 16 |
| Hurdle (Req g minus delivered) | +6.5 pp | +5.7 pp | 8th most demanding of 16 |
| ROIC minus cost of capital | -3.4 pp | -4.1 pp | 10th highest of 20 |
| EV / EBITDA | 16.1× | 11.9× | 6th most expensive of 13 |
| Net debt / EBITDA | 2.9× | 1.1× | 7th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AddLife ALIF-B.ST | Sweden | $2.13B | +15% | +2% | 8% | 39.0× | 21.1% | +14.6% |
| Azenta AZTA | United States | $2.03B | +162% | +5% | -2% | 83.2× | 38.0% | +3.9% |
| Addus HomeCare ADUS | United States | $2.25B | +29% | +12% | 11% | 16.2× | 4.0% | +13.2% |
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 53.5× | n/a | n/a |
| Aveanna Healthcare AVAH | United States | $2.37B | +41% | +17% | 12% | 12.2× | 7.7% | +10.2% |
| Pediatrix Medical MD | United States | $2.41B | +37% | +2% | 12% | 12.4× | -4.4% | +2.0% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% | +26.9% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.60B | -27% | -4% | 9% | 49.6× | 4.2% | +5.7% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |